Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Q4 2020 Earnings Presentation
20 slides from Evofem Biosciences's earnings presentation, Mar 4, 2021
Slide 1: Q4 and Year-End 2020 Financial Results Call
Evofem Biosciences’ Q4 and Year-End 2020 Financial Results Call Nasdaq: EVFM Thursday, March 4, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,
Slide 3: 2020 Highlights: Foundation for Ongoing Success
FOR INVESTOR DISCUSSIONS ONLY. NOT FOR PROMOTIONAL USE.3 • Phexxi FDA approved and launched in U.S. •Ongoing prescription growth, expansion of prescriber base, market access execution • Two Phexxi patents listed in FDA’s Orange Book •Raised over $150M from respected institutional investors • Initiat
Slide 4: Financial Highlights
FOR INVESTOR DISCUSSIONS ONLY. NOT FOR PROMOTIONAL USE.4 Financial Highlights March 4, 2021 • Net product revenue for Q4 and FY 2020 reflected strong co-pay card utilization, as expected • Beat or met guidance on expense and cash burn for Q4 and FY 2020 • At December 31, 2020 o$48.9M in unrestricted
Slide 5: Unit Shipments from Warehouse to Wholesalers on Track to Exceed FY 2020 Levels
5292 3288 5952 Q3 2020 Q4 2020 Q1 2021* Through Feb. 26, 2021 Q1 2021 Unit Shipments from Warehouse to Wholesalers on Track to Exceed FY 2020 Levels March 4, 2021 Initial stocking orders FOR INVESTOR DISCUSSIONS ONLY. NOT FOR PROMOTIONAL USE. 2 of 3 months
Slide 6: The Time is Right for Phexxi
FOR INVESTOR DISCUSSIONS ONLY. NOT FOR PROMOTIONAL USE. The Time is Right for Phexxi In the US today, there are 21 million women at risk for pregnancy who are NOT using hormonal contraception1 6 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCH
Slide 7: US Contraceptive Market and Phexxi Peak Revenue Potential
Sterilization, other non-targets - 32.5M Non-Rx Contraceptive Users 10.3M No Contraceptive - 10.6M Rx Contraceptive Users - 18.8M US Contraceptive Market: 72.2M Women1 $2.3 BILLION Peak Revenue Potential $670M - $860M $375M - $690M Phexxi Peak Revenue (gross, est.) $1.4B - $2.3B3 Rx Targets 1.0% - 2
Slide 8: Sales Unit Growth from Wholesalers to Pharmacies Signifies Increasing Demand
Sales Unit Growth from Wholesalers to Pharmacies Signifies Increasing Demand 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 August'20 September'20 October'20 November'20 December'20 January'21 February'21 P he xx i U ni ts Monthly Units: Wholesalers to Pharmacies Monthly TRx Source: Sales Units fro
Slide 9: Monthly Prescription Growth
Monthly Prescription Growth1 375 967 1100 1378 1542 951 4 46 133 231 236 134 0 250 500 750 1000 1250 1500 1750 2000 Sept. 2020 Oct. 2020 Nov. 2020 Dec. 2020 Jan. 2021 Feb. 2021 Refills NRx 1233 379 1013 1609 1. IQVIA (including Knipper) monthly data through 31 Jan 2021 * IQVIA (including Knipper) da
Slide 10: Over 2,650 HCPs Have Prescribed Phexxi Since Launch
2 229 476 531 590 550 298 1 72 181 297 392 314 2 230 548 712 887 942 0 250 500 750 1,000 1,250 Aug. '20 Sep. '20 Oct. '20 Nov. '20 Dec. '20 Jan. '21 Feb. '21 HCPs Prescribing Phexxi Returning New Prescribers through 2/12/21 only Over 2,650 HCPs Have Prescribed Phexxi Since Launch IQVIA data through
Slide 11: Get Phexxi – Rollout
TELEVISION YOUTUBE SOCIAL MEDIA PHEXXI.COM DIGITAL MEDIA PRINT MATERIALS GET PHEXXI – ROLLOUT
Slide 12: Get Phexxi – Impact
•2X increase in Phexxi total brand awareness over January -- grew to 8%1 •115M+ video views2 GET PHEXXI – IMPACT Telehealth clicks3 969% Telehealth Appointments 4 7x 100% Phexxi Prescription Fulfillment 4 from 2/15 -2/22 362% Increase in organic (unpaid) search for “Phexxi” in search engines 3 200%
Slide 13: Phexxi for Cancer Patients: NCODA Collaboration
Phexxi for Cancer Patients: NCODA Collaboration • ~800,000 new cases of cancer reported annually among women1 • Many women with cancer are contraindicated to hormones • Collaboration to develop and share resources and educational information for medically-integrated oncology pharmacy teams involved
Slide 14: Market Access
Market Access Channel % of Lives Covered (2/12/21) Commercial 55.1% Medicaid 100.0% Notes: • Covered means patient has access to Phexxi, whether unrestricted or restricted access (i.e. prior authorizations or step therapy (trial of another product before Phexxi would be approved)) • Commercial lives
Slide 15: STI Prevention Market Opportunity
STI Prevention Market Opportunity • 78M sexually active women potentially at risk for STIs (US)4 • Chlamydia and Gonorrhea infections are on the rise oUS chlamydia and gonorrhea infection rates increased for 5th consecutive year despite availability of condoms for STI prevention1,2 oGlobal incidence
Slide 16: EVOGUARD Phase 3 Trial Underway
EVOGUARD Phase 3 Trial Underway • Phase 3, double-blind, placebo-controlled study to evaluate the efficacy of EVO100 in the prevention of urogenital Chlamydia trachomatis (CT) and Neisseria gonorrhea (GC) infection o16-week treatment phase, 4-week follow up • Enrolling 1,730 healthy women at 90 site
Slide 17: EVO100: Expected Timeline to Approval
EVO100: Expected Timeline to Approval 2021 2022 2023 Potential US Approval & Commercial Launch NDA submission2 Top-Line Results1 Initiate Pivotal Phase 3 Trial • FDA Fast Track designation for prevention of chlamydia in women • FDA QIDP designation for prevention of gonorrhea in women o Potential 5-
Slide 18: Get Phexxi
FOR INVESTOR DISCUSSIONS ONLY. NOT FOR PROMOTIONAL USE. 18 DO IT on the floor. G E T P H E X X I® , T H A T I S .
Slide 19: Questions and Answers
QUESTIONS AND ANSWERS
Slide 20: Evofem Biosciences
E¥OFEM BIOSCIENCE S®